SXTP Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q2

FY2025Q3

FY2025Q4

300.00K

+140.06%

-1.280

-93.77%

400.00K

+195.66%

-1.380

-68.19%

400.00K

+65.54%

-1.340

-84.2%

Estimates Revision

The market is revising No Change the revenue expectations for 60 Degrees Pharmaceuticals, Inc. (SXTP) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -68.38%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Down

-68.38%

In Past 3 Month

1 Analyst Rating

Wall Street analysts forecast SXTP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SXTP is 3.40 USD with a low forecast of 3.40 USD and a high forecast of 3.40 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

0 Buy

1 Hold

0 Sell

Hold

Current: 0.000

Low

3.40

Averages

3.40

High

3.40

Current: 0.000

Low

3.40

Averages

3.40

High

3.40

H.C. Wainwright

Buy

initiated

2025-11-14

Reason

H.C. Wainwright

Price Target

2025-11-14

initiated

Buy

Reason

H.C. Wainwright assumed coverage of 60 Degrees Pharmaceuticals with a Buy rating and $6 price target. The firm says 60 Degrees is "flying under the radar with investors." Tafenoquine is a differentiated, FDA approved product that is already on the market and has demonstrated "impressive" initial clinical activity in babesiosis, the analyst tells investors in a research note.

HC Wainwright & Co.

Edward White

Hold

Reiterates

n/a

2025-03-28

Reason

HC Wainwright & Co.

Edward White

Price Target

n/a

2025-03-28

Reiterates

Hold

Reason

HC Wainwright & Co.

Edward White

Hold

Reiterates

n/a

2025-01-10

Reason

HC Wainwright & Co.

Edward White

Price Target

n/a

2025-01-10

Reiterates

Hold

Reason

Valuation Metrics

The current forward P/E ratio for 60 Degrees Pharmaceuticals Inc (SXTP.O) is -0.14, compared to its 5-year average forward P/E of -0.88. For a more detailed relative valuation and DCF analysis to assess 60 Degrees Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-0.88

Current PE

-0.14

Overvalued PE

-0.02

Undervalued PE

-1.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.84

Current PS

1.47

Overvalued PS

10.59

Undervalued PS

-0.91

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

SXTP News & Events

Events Timeline

No data

News

2.0

2025-12-29Globenewswire

60 Degrees Pharma Confirms B-FREE Study for ARAKODA® in Chronic Babesiosis Treatment

9.0

2025-12-29Newsfilter

60 Degrees Pharma Confirms B-FREE Study for ARAKODA in Chronic Babesiosis Treatment

7.5

2025-12-11Globenewswire

60 Degrees Pharma Expands Sales Team to Boost ARAKODA Sales

People Also Watch

Frequently Asked Questions

What is 60 Degrees Pharmaceuticals Inc (SXTP) stock price today?

The current price of SXTP is 0.51705 USD — it has increased 0.98 % in the last trading day.

What is 60 Degrees Pharmaceuticals Inc (SXTP)'s business?

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

What is the price predicton of SXTP Stock?

What is 60 Degrees Pharmaceuticals Inc (SXTP)'s revenue for the last quarter?

60 Degrees Pharmaceuticals Inc revenue for the last quarter amounts to 256.28K USD, increased 75.42 % YoY.

What is 60 Degrees Pharmaceuticals Inc (SXTP)'s earnings per share (EPS) for the last quarter?

60 Degrees Pharmaceuticals Inc. EPS for the last quarter amounts to -1.55 USD, decreased -183.78 % YoY.

What changes have occurred in the market's expectations for 60 Degrees Pharmaceuticals Inc (SXTP)'s fundamentals?

How many employees does 60 Degrees Pharmaceuticals Inc (SXTP). have?

60 Degrees Pharmaceuticals Inc (SXTP) has 3 emplpoyees as of January 09 2026.

What is 60 Degrees Pharmaceuticals Inc (SXTP) market cap?

Today SXTP has the market capitalization of 3.28M USD.